Nuventra is proud to announce that David Y. Mitchell, Ph.D., Chief Scientific Officer, has been elected as President-Elect of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Dr. Mitchell will serve as President-Elect starting in March 2018, and his term as President will begin in March 2019.
ASCPT was founded in 1900 as the American Therapeutic Society. ASCPT now consists of over 2,300 professionals whose primary interest is to advance the science and practice of clinical pharmacology and translational medicine for the therapeutic benefit of patients and society. ASCPT is the largest scientific and professional organization serving the disciplines of Clinical Pharmacology and Translational Medicine.
During his term as President, Dr. Mitchell and the leadership team will revise the strategic plan to provide direction and continuity to the association from 2020 to 2025. In addition, Dr. Mitchell hopes to continue building a diverse membership, use subcommittees to groom members as future leaders of the organization, and collaborate with medical and scientific associations and health authorities to enhance the breadth and depth of the science for the members.
“I’m grateful for the opportunity to serve this organization which has contributed so much to the clinical pharmacology community. I hope to follow in the footsteps of the great leaders of ASCPT and continue to add value for our members,” says Dr. Mitchell.
Dr. Mitchell and several other members of Nuventra’s team look forward to attending ASCPT’s annual meeting in March 2018. For more information about the meeting, visit http://www.ascpt.org/ASCPT-2018-Annual-Meeting